Body Pharm Retatrutide 64mg

The Body Pharm Retatrutide 64mg injection pen is a UK-dispatched multi-dose research format containing twice the total peptide capacity of the 32mg pen, designed for in vitro and laboratory protocols requiring extended titration simulations of the GIP, GLP-1 and glucagon triple-receptor agonist LY3437943 [5]. We ship from UK stock with batch-level traceability against HPLC and mass-spectrometry analytical records [3].

Retatrutide is an investigational triple agonist still in active Phase 3 obesity development under Eli Lilly's J1I-MC-GZBJ master protocol, with no MHRA or EMA marketing authorisation as of 2026 [4][5]. We supply it strictly as an unlicensed research peptide, not for human consumption [7]. The 64mg pen suits research groups modelling the 2 mg → 12 mg/week escalation pattern reported by Jastreboff et al. (NEJM, 2023) without re-procuring mid-study [6].

Key Takeaways

• The 64mg pen holds double the peptide load of the 32mg format, removing the need for mid-protocol pen changes in extended titration studies
• Retatrutide activates three receptors (GIP, GLP-1, glucagon) simultaneously, producing a mean 24.2% body-weight reduction at 48 weeks in Phase 2 trials
• Every batch includes third-party HPLC and mass-spectrometry analysis with batch-specific traceability documentation
• Retatrutide remains unlicensed in the UK as of 2026 and is supplied strictly for laboratory research, not human use
• UK delivery is free via Royal Mail Tracked 24, dispatching the same working day for orders placed before 14:00 GMT

What Is Retatrutide 64mg?

Retatrutide is a synthetic incretin-mimetic peptide and triple-receptor agonist that activates the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon receptors simultaneously, originally developed by Eli Lilly under the code LY3437943 [1][3]. The "64mg" figure denotes the total peptide load in a single pre-filled multi-dose pen (a 3 mL cartridge), not a per-dose strength. The pen dials each dose directly in milligrams — every step of the ladder, up to the 12 mg maximum — and is supplied ready to use for subcutaneous administration [3].

The 64mg capacity covers a complete simulated titration arc without re-procurement. In the Jastreboff et al. Phase 2 obesity trial (NEJM, 2023), retatrutide produced a mean body-weight reduction of up to 24.2% at 48 weeks in the highest-dose cohort, following a 2 mg starting dose escalated every four weeks to 12 mg weekly [1][2]. That figure remains the most recent peer-reviewed efficacy benchmark, with Phase 3 readouts under master protocol J1I-MC-GZBJ still pending as of 2026 [3].

Whether a 64mg pen is necessary depends on study duration and dose escalation. If your protocol runs longer than 8 weeks at mid-to-high doses, the 64mg format removes a mid-study pen change and reduces cost-per-mg.

Researchers comparing mechanisms before committing should review our retatrutide vs semaglutide vs tirzepatide breakdown, whilst those finalising study design will find protocol scaffolding in how to dose retatrutide.

Triple-Receptor Mechanism: GIP, GLP-1 & Glucagon

Retatrutide activates three metabolic pathways in a single molecule. That is its primary pharmacological advantage over dual agonists: tirzepatide engages only GIP and GLP-1; semaglutide engages GLP-1 alone [1]. Each receptor contributes a distinct metabolic action, and the combination underpins the 24.2% mean weight reduction reported at 48 weeks in the Jastreboff et al. Phase 2 trial [1].

GIP (glucose-dependent insulinotropic polypeptide) drives glucose-dependent insulin secretion from pancreatic beta cells and modulates adipose tissue lipid handling.

GLP-1 (glucagon-like peptide-1) suppresses appetite via central hypothalamic signalling and slows gastric emptying, reducing post-prandial glucose excursions.

Glucagon receptor increases hepatic glucose output acutely but, under chronic agonism, raises basal energy expenditure and promotes hepatic lipid oxidation.

The glucagon arm is the main pharmacological differentiator versus tirzepatide. The added thermogenic and hepatic-lipid effect is hypothesised to account for the larger weight-loss magnitude observed in Phase 2 compared with dual GIP/GLP-1 agonism [1]. Some researchers are concerned that glucagon agonism may increase hepatic glucose output excessively; Phase 2 data suggest this is offset by improved lipid oxidation and energy expenditure under chronic dosing, though Phase 3 data remain pending. Researchers modelling comparative pharmacodynamics should consult our retatrutide vs semaglutide vs tirzepatide breakdown before finalising compound selection.

32mg vs 64mg Pen: Which Format for Your Research?

The 64mg pen carries double the peptide load of the 32mg pen and is the right choice for research protocols extending beyond 8 weeks at mid-to-high titration doses. It removes a mid-protocol pen change and lowers cost-per-mg. The 32mg pen suits shorter pilot studies or low-dose tolerability work where total mg requirements stay under approximately 30mg across the run.

The 2mg start and 4-weekly escalation used in the Jastreboff Phase 2 obesity trial reached 12mg/week maintenance [6]. We recommend the 64mg pen for any protocol mirroring that schedule. For a short tolerability screen, the Retatrutide 32mg pen is sufficient. See our how to dose retatrutide guide to map weekly increments against pen capacity before ordering.

Product Specifications

The Body Pharm Retatrutide 64mg pen is a pre-filled multi-dose subcutaneous injection device containing 64mg of retatrutide (LY3437943) in a 3 mL cartridge, a synthetic GIP/GLP-1/glucagon triple receptor agonist developed by Eli Lilly and currently in Phase 3 obesity trials [5][4]. The pen is supplied ready to use as a single sealed unit in tamper-evident outer packaging with batch number and CoA (Certificate of Analysis) reference printed on the carton.

Store the pen at 2–8 °C, protected from light, and never freeze it. Unopened shelf life is 24 months; once first used, the pen keeps for 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. Request the current CoA via our support channel before logging into your procurement system, as purity assay values vary between production runs.

The pen dials each dose directly in milligrams — every step of the ladder, up to the 12 mg maximum — with no volume calculation or click-counting. For titration mapping against the 2mg→12mg/week Jastreboff schedule [1], see the how to dose retatrutide guide. Researchers comparing this pen against semaglutide or tirzepatide formats should consult retatrutide vs semaglutide vs tirzepatide before finalising the procurement record.

Quality, Purity & Batch Traceability

Every batch we dispatch from our UK fulfilment hub in 2026 is filled and sealed under cleanroom-controlled conditions aligned with EU GMP (Good Manufacturing Practice) principles for research peptides. Each pen is tied to a unique batch number printed on the outer carton and cross-referenced in our internal CoA register. We commission third-party HPLC (high-performance liquid chromatography) and mass spectrometry analysis on every production run, and we will not release a batch into UK dispatch unless the HPLC chromatogram and identity confirmation are on file.

To request the CoA for your allocated batch, email our support address with the batch number on your carton. We return the signed PDF within one working day. Retatrutide remains an unlicensed investigational compound in the UK as of 2026 [3][5], so traceability documentation is the primary integrity check available to procurement teams. Researchers cross-referencing analytical specifications against other incretin analogues should consult our retatrutide vs semaglutide vs tirzepatide comparison before sign-off.

Ordering, Shipping & Returns

UK orders ship free via Royal Mail Tracked 24 in plain, unbranded outer packaging, with estimated delivery of 1–3 working days from dispatch. We dispatch all 64mg pens from our UK fulfilment hub the same working day when the order is placed before 14:00 GMT. A tracking reference is emailed automatically once the label is generated.

Discreet packaging is standard on every consignment: no Body Pharm branding, no product descriptors, and no temperature stickers on the outer carton. This matters for researchers receiving deliveries at shared institutional or residential addresses. Returns are accepted on unused, unopened items within 14 days of delivery. Opened or used pens cannot be returned for sterility and chain-of-custody reasons.

We currently ship to UK addresses only. Researchers planning a titration protocol after receipt should review our how to dose retatrutide guide; the pen is pre-filled, so no reconstitution is needed.

Research Use Only: UK Regulatory Context

Body Pharm Retatrutide 64mg is sold strictly for laboratory research and analytical purposes and is not for human consumption. Retatrutide does not hold a UK marketing authorisation as of 2026 and falls under the MHRA's (Medicines and Healthcare products Regulatory Agency) general framework for unlicensed medicinal products and investigational compounds, not as a licensed therapeutic [5]. Eli Lilly's Phase 3 obesity programme for retatrutide (master protocol J1I-MC-GZBJ) remains in active follow-up with no NDA (New Drug Application) or MAA (Marketing Authorisation Application) filing recorded in 2024–2026 pipeline disclosures [1][2].

UK research suppliers, including Body Pharm, label retatrutide as "for laboratory research only" in line with this unlicensed status [3][4]. Procurement professionals should consult their institution's ethics committee and procurement policy before placing an order and verify the current MHRA position at the time of purchase. Researchers comparing incretin candidates before ordering may find our retatrutide vs semaglutide vs tirzepatide breakdown useful. We do not provide human dosing guidance.

Retatrutide Dosing Protocols for Research

The Jastreboff et al. 2023 NEJM Phase 2 obesity trial used a starting dose of 2 mg once weekly with dose escalation every 4 weeks, reaching a maximum tested maintenance dose of 12 mg/week [1][2]. Common escalation arms followed a stepwise 2 mg → 4 mg → 8 mg → 12 mg weekly pattern, with intermediate maintenance ceilings at 4 mg and 8 mg also evaluated [1][2]. These figures are reference points for research design only and do not constitute human dosing guidance.

The 64mg pen carries double the total peptide payload of the 32mg format, which is why it suits multi-week in vitro titration simulations or extended analytical runs without a mid-study pen change. Both pens dial the dose directly in milligrams, so there is no reconstitution or dilution maths; for titration modelling against the published trial schedule, see our how to dose retatrutide guide.

Frequently Asked Questions

Is retatrutide legal to purchase in the UK?

Retatrutide is legal to purchase in the UK strictly for laboratory research, not for human use, because it remains an unlicensed investigational medicinal product with no MHRA marketing authorisation as of 2026 [5]. UK vendors must label it "for research use only" to remain compliant with the MHRA's general unlicensed-medicines framework [5][4].

How does the 64mg pen differ from the 32mg pen?

The 64mg pen carries double the total peptide payload of the 32mg format, supporting extended in vitro titration runs without a mid-study pen change. Both pens use the same triple-agonist compound (LY3437943); only total capacity differs. For titration modelling against the 2 mg → 12 mg/week trial schedule, see our how to dose retatrutide guide [1].

How should the pen be stored?

Store the pen at 2–8 °C, protected from light, and never freeze it. Unopened shelf life is 24 months; once first used, the pen keeps for 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days.

Is a certificate of analysis available?

Yes. Every batch ships with a batch-specific CoA covering HPLC purity and mass-spectrometry identity confirmation, available on request with the order reference.

How long does UK delivery take?

We dispatch from a UK fulfilment address with tracked next-day delivery on orders placed before 14:00 GMT Monday–Friday. Researchers comparing compounds pre-purchase can review our retatrutide vs semaglutide vs tirzepatide breakdown.

Next Steps

Review the how to dose retatrutide guide to map your protocol's titration schedule against the 64mg pen capacity, then consult your institution's procurement and ethics teams before placing an order. If you need batch-specific analytical data or have questions about storage and handling, contact our support team with your intended study timeline.

References

1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
2. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
3. Retatrutide (LY3437943) triple-receptor agonist (Eli Lilly); molecule characterisation and analytical/formulation reference — Phase 3 readouts pre-publication as of 2026.
4. Retatrutide (LY3437943) Phase 3 obesity programme (Eli Lilly, master protocol J1I-MC-GZBJ), pre-publication as of 2026 — no journal paper available.
5. UK regulatory status — retatrutide holds no MHRA or EMA marketing authorisation and is supplied for laboratory research use only as of 2026.
6. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
7. UK regulatory status — retatrutide is an unlicensed investigational compound supplied strictly for research, not human consumption, as of 2026.